Literature DB >> 22508310

The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections.

Bing Zhai1, Cheng Wu, Linqi Wang, Matthew S Sachs, Xiaorong Lin.   

Abstract

Therapeutic treatment for systemic mycoses is severely hampered by the extremely limited number of antifungals. The difficulty of treatment of fungal infections in the central nervous system is further compounded by the poor central nervous system (CNS) penetration of most antifungals due to the blood-brain barrier. Only a few fungistatic azole drugs, such as fluconazole, show reasonable CNS penetration. Here we demonstrate that sertraline (Zoloft), the most frequently prescribed antidepressant, displays potent antifungal activity against Cryptococcus neoformans, the major causative agent of fungal meningitis. In in vitro assays, this neurotropic drug is fungicidal to all natural Cryptococcus isolates tested at clinically relevant concentrations. Furthermore, sertraline interacts synergistically or additively with fluconazole against Cryptococcus. Importantly, consistent with our in vitro observations, sertraline used alone reduces the brain fungal burden at an efficacy comparable to that of fluconazole in a murine model of systemic cryptococcosis. It works synergistically with fluconazole in reducing the fungal burden in brain, kidney, and spleen. In contrast to its potency against Cryptococcus, sertraline is less effective against strains of Candida species and its interactions with fluconazole against Candida strains are often antagonistic. Therefore, our data suggest the unique application of sertraline against cryptococcosis. To understand the antifungal mechanisms of sertraline, we screened a whole-genome deletion collection of Saccharomyces cerevisiae for altered sertraline susceptibility. Gene ontology analyses of selected mutations suggest that sertraline perturbs translation. In vitro translation assays using fungal cell extracts show that sertraline inhibits protein synthesis. Taken together, our findings indicate the potential of adopting this antidepressant in treating cryptococcal meningitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508310      PMCID: PMC3393448          DOI: 10.1128/AAC.00212-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity.

Authors:  T J Young; G P Oliver; D Pryde; M Perros; T Parkinson
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

2.  In vitro activity of nonsteroidal anti-inflammatory agents, phenotiazines, and antidepressants against Brucella species.

Authors:  S Muñoz-Criado; J L Muñoz-Bellido; J A García-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

3.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

4.  Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog.

Authors:  L M Tremaine; W M Welch; R A Ronfeld
Journal:  Drug Metab Dispos       Date:  1989 Sep-Oct       Impact factor: 3.922

5.  Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro.

Authors:  C Lass-Flörl; M P Dierich; D Fuchs; E Semenitz; I Jenewein; M Ledochowski
Journal:  J Antimicrob Chemother       Date:  2001-12       Impact factor: 5.790

6.  A 2-year study of sertraline in the treatment of obsessive-compulsive disorder.

Authors:  S Rasmussen; E Hackett; E DuBoff; J Greist; A Halaris; L M Koran; M Liebowitz; R B Lydiard; S McElroy; J Mendels; K O'Connor
Journal:  Int Clin Psychopharmacol       Date:  1997-11       Impact factor: 1.659

7.  Arginine-specific regulation mediated by the Neurospora crassa arg-2 upstream open reading frame in a homologous, cell-free in vitro translation system.

Authors:  Z Wang; M S Sachs
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

Review 8.  Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.

Authors:  T G Mitchell; J R Perfect
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Translationally controlled tumor protein is a target of tumor reversion.

Authors:  Marcel Tuynder; Giusy Fiucci; Sylvie Prieur; Alexandra Lespagnol; Anne Géant; Séverine Beaucourt; Dominique Duflaut; Stéphanie Besse; Laurent Susini; Jean Cavarelli; Dino Moras; Robert Amson; Adam Telerman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

Review 10.  The antidepressant effects of 5-HT uptake inhibitors.

Authors:  A Aberg-Wistedt
Journal:  Br J Psychiatry Suppl       Date:  1989-12
View more
  77 in total

1.  Cryptococcal Meningitis: Diagnosis and Management Update.

Authors:  Mahsa Abassi; David R Boulware; Joshua Rhein
Journal:  Curr Trop Med Rep       Date:  2015-06-01

2.  Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp.

Authors:  Suélen Andreia Rossi; Haroldo Cesar de Oliveira; Daniel Agreda-Mellon; José Lucio; Maria José Soares Mendes-Giannini; Jesús Pablo García-Cambero; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 4.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

5.  Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.

Authors:  Andrew Katende; Gladys Mbwanji; Diana Faini; Amina Nyuri; Aneth Vedastus Kalinjuma; Dorcas Mnzava; Katherine H Hullsiek; Joshua Rhein; Maja Weisser; David B Meya; David R Boulware; Emilio Letang
Journal:  Mycoses       Date:  2019-10-21       Impact factor: 4.377

Review 6.  Antifungal drug development: challenges, unmet clinical needs, and new approaches.

Authors:  Terry Roemer; Damian J Krysan
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-01       Impact factor: 6.915

7.  A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.

Authors:  Arielle Butts; Louis DiDone; Kristy Koselny; Bonnie K Baxter; Yeissa Chabrier-Rosello; Melanie Wellington; Damian J Krysan
Journal:  Eukaryot Cell       Date:  2012-12-14

8.  Congenic strains for genetic analysis of virulence traits in Cryptococcus gattii.

Authors:  Pinkuan Zhu; Bing Zhai; Xiaorong Lin; Alexander Idnurm
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

9.  Congenic strains of the filamentous form of Cryptococcus neoformans for studies of fungal morphogenesis and virulence.

Authors:  Bing Zhai; Pinkuan Zhu; Dylan Foyle; Srijana Upadhyay; Alexander Idnurm; Xiaorong Lin
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

10.  Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.

Authors:  Kyle D Smith; Beatrice Achan; Kathy Huppler Hullsiek; Tami R McDonald; Laura H Okagaki; Ali A Alhadab; Andrew Akampurira; Joshua R Rhein; David B Meya; David R Boulware; Kirsten Nielsen
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.